These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 20877372
41. [Atypical hemolytic uremic syndrome and the CFH gene]. Jiang CR, Ye LY, Yu ZH. Zhonghua Er Ke Za Zhi; 2008 Dec; 46(12):952-5. PubMed ID: 19134264 [No Abstract] [Full Text] [Related]
43. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Boels MG, Lee DH, van den Berg BM, Dane MJ, van der Vlag J, Rabelink TJ. Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408 [Abstract] [Full Text] [Related]
44. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Proc Natl Acad Sci U S A; 2007 Jan 02; 104(1):240-5. PubMed ID: 17182750 [Abstract] [Full Text] [Related]
45. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. PLoS Genet; 2007 Mar 16; 3(3):e41. PubMed ID: 17367211 [Abstract] [Full Text] [Related]
46. A user's guide to the interactive Web database of factor H-associated hemolytic uremic syndrome. Saunders RE, Perkins SJ. Semin Thromb Hemost; 2006 Mar 16; 32(2):160-8. PubMed ID: 16575691 [Abstract] [Full Text] [Related]
47. The development of atypical hemolytic uremic syndrome depends on complement C5. de Jorge EG, Macor P, Paixão-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC. J Am Soc Nephrol; 2011 Jan 16; 22(1):137-45. PubMed ID: 21148255 [Abstract] [Full Text] [Related]
48. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Am J Kidney Dis; 2008 Jul 16; 52(1):171-80. PubMed ID: 18423815 [Abstract] [Full Text] [Related]
50. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V. Kidney Int; 2010 Feb 16; 77(4):339-49. PubMed ID: 20016463 [Abstract] [Full Text] [Related]
51. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Mol Immunol; 2007 Jan 16; 44(1-3):111-22. PubMed ID: 16882452 [Abstract] [Full Text] [Related]
52. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, Frémeaux-Bacchi V. Methods Mol Biol; 2014 Jan 16; 1100():237-47. PubMed ID: 24218264 [Abstract] [Full Text] [Related]
53. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Kim JJ, Goodship TH, Tizard J, Inward C. Pediatr Nephrol; 2011 Nov 16; 26(11):2073-6. PubMed ID: 21717289 [Abstract] [Full Text] [Related]
54. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, Atkinson JP. Clin J Am Soc Nephrol; 2007 May 16; 2(3):591-6. PubMed ID: 17699467 [No Abstract] [Full Text] [Related]
55. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Frémeaux-Bacchi V. J Med Genet; 2009 Jul 16; 46(7):447-50. PubMed ID: 19435718 [Abstract] [Full Text] [Related]
56. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L, Ward R, Plant N, Nailescu C, Goodship TH, Marchbank KJ. Clin J Am Soc Nephrol; 2012 Mar 16; 7(3):417-26. PubMed ID: 22223611 [Abstract] [Full Text] [Related]
57. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Chaudhary P, Hepgur M, Sarkissian S, Smith RJ, Weitz IC. Blood Transfus; 2014 Jan 16; 12(1):111-3. PubMed ID: 24333077 [No Abstract] [Full Text] [Related]
58. Anti-complement factor H (CFH) antibodies and a novel CFH gene mutation in an atypical hemolytic uremic syndrome patient with complement activation of the classical pathway. Minato S, Iijima H, Nakao H, Nishi K, Hidaka Y, Inoue N, Kubota M, Ishiguro A. Immunol Med; 2021 Dec 16; 44(4):274-277. PubMed ID: 33784485 [Abstract] [Full Text] [Related]
59. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Boyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-Durey MA, Frémeaux-Bacchi V, Niaudet P. Am J Kidney Dis; 2010 May 16; 55(5):923-7. PubMed ID: 20202729 [Abstract] [Full Text] [Related]
60. Atypical hemolytic uremic syndrome due to factor H autoantibody. Uslu-Gökceoğlu A, Doğan CS, Comak E, Koyun M, Akman S. Turk J Pediatr; 2013 May 16; 55(1):86-9. PubMed ID: 23692839 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]